RA measures in the QUEST–RA study in Europe and other countries, in descending order of GDP
| Country | GDP 2005 per capita (US$1000) | DAS28 (0–9.1), mean | SJC (0–28), median | TJC (0–28), median | Physician global (0–10), median | HAQ physical function (0–3), median | Pain VAS (0–10), median | Patient global VAS (0–10), median | PS-HAQ (0–3), mean | ESR, median | RF-positive, % | Erosive disease, % |
| Europe | ||||||||||||
| Ireland | 48.7 | 4.1 | 3 | 4 | 1.6 | 0.75 | 3.4 | 2.9 | 0.61 | 18 | 80 | 60 |
| Denmark | 47.9 | 3.4 | 1 | 2 | 1.3 | 0.63 | 2.6 | 2.8 | 0.53 | 14 | 73 | 64 |
| Sweden | 39.6 | 3.8 | 2 | 2 | 1.4 | 0.88 | 3.3 | 3.3 | 0.56 | 19 | 82 | 60 |
| The Netherlands | 38.9 | 3.1 | 1 | 0 | 0.7 | 0.75 | 2.5 | 2.7 | 0.54 | 15 | 69 | 44 |
| Finland | 37.3 | 3.3 | 1 | 1 | 0.9 | 0.63 | 2.8 | 2.8 | 0.46 | 13 | 75 | 56 |
| UK | 37.3 | 4.0 | 1 | 4 | 1.8 | 0.88 | 4.1 | 3.6 | 0.69 | 19 | 81 | 69 |
| France | 35.0 | 3.7 | 1 | 2 | 2.5 | 0.88 | 3.9 | 3.6 | 0.90 | 16 | 75 | 76 |
| Germany | 33.9 | 4.4 | 3 | 4 | 3.0 | 0.75 | 5.0 | 4.9 | 0.81 | 20 | 61 | 78 |
| Italy | 30.5 | 4.5 | 2 | 4 | 3.0 | 1.00 | 4.9 | 5.0 | 0.97 | 28 | 71 | 38 |
| Spain | 26.1 | 3.5 | 1 | 1 | 1.2 | 0.88 | 3.1 | 3.6 | 0.88 | 17 | 73 | 60 |
| Greece | 25.6 | 3.4 | 0 | 1 | 1.1 | 0.25 | 2.3 | 2.0 | 0.77 | 23 | 52 | 71 |
| Hungary | 10.9 | 5.1 | 5 | 7 | 3.3 | 1.38 | 5.2 | 5.1 | 1.08 | 26 | 93 | 93 |
| Estonia | 10.3 | 4.7 | 4 | 6 | 3.0 | 1.13 | 4.3 | 4.8 | 0.95 | 24 | 68 | 86 |
| Poland | 8.0 | 5.3 | 6 | 9 | 4.3 | 1.38 | 5.0 | 4.8 | 0.97 | 31 | 70 | 62 |
| Lithuania | 7.5 | 5.5 | 3 | 12 | 4.1 | 1.38 | 5.2 | 5.3 | 1.01 | 29 | 78 | 79 |
| Latvia | 7.0 | 5.2 | 4 | 8 | 4.9 | 1.38 | 5.1 | 5.7 | 0.93 | 26 | 85 | 97 |
| Serbia | 3.5 | 5.9 | 6 | 18 | 4.6 | 1.63 | 5.1 | 5.3 | 1.38 | 28 | 71 | 80 |
| Kosovo | 3.5 | 6.0 | 6 | 16 | 4.7 | 1.63 | 5.1 | 5.0 | 1.47 | 45 | 81 | 99 |
| Non-Europe | ||||||||||||
| USA | 41.9 | 3.3 | 2 | 1 | 1.9 | 0.63 | 3.2 | 2.6 | 0.47 | 14 | 71 | 36 |
| Canada | 35.2 | 4.1 | 2 | 4 | 1.8 | 1.00 | 4.6 | 4.0 | 0.69 | 21 | 83 | 45 |
| UAE | 32.4 | 4.3 | 3 | 3 | 2.6 | 0.63 | 3.7 | 2.8 | 0.69 | 24 | 75 | 47 |
| Russia | 5.3 | 5.0 | 5 | 6 | 3.4 | 1.13 | 3.5 | 4.5 | 1.21 | 24 | 75 | 60 |
| Turkey | 5.0 | 4.2 | 0 | 2.5 | 2.0 | 0.88 | 4.2 | 4.6 | 0.94 | 30 | 68 | 56 |
| Brazil | 4.8 | 4.2 | 3 | 2 | 1.5 | 0.63 | 3.2 | 3.5 | 0.71 | 28 | 80 | 63 |
| Argentina | 4.7 | 5.3 | 9 | 10.5 | 4.7 | 1.00 | 5.0 | 4.7 | 1.13 | 30 | 90 | 68 |
| Total | 4.2 | 2 | 4 | 2.4 | 0.88 | 4.1 | 4.2 | 0.82 | 22 | 74 | 63 |
DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; GDP, gross domestic product; HAQ, health assessment questionnaire; Physician global, physician global estimate of status; PS-HAQ, psychological HAQ; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; UAE, United Arab Emirates; VAS, visual analogue scale.